Share on

Asia Pacific Contraceptives Market Research Report – Segmented By Drug Type, Medical Devices, End-Users, Country (India, China, Japan, Australia, New Zealand, ASEAN Countries and Rest of APAC) - Industry Analysis, Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 1157
Pages: 136
Formats: report pdf report excel report power bi report ppt

APAC Contraceptives Market Size (2023 to 2028)

As per our report, the Asia Pacific Contraceptives Market size was worth USD 5.74 billion in 2023 and is estimated to reach USD 8.04 billion by the end of 2028, with a growing potential of 6.95%.

Increasing awareness about contraceptive methods among the population is the primary factor for the market's growth. Due to the increasing literacy rate in the region, more than half of the population are known about contraceptive methods. In India, most people use IUDs (Intrauterine devices) contraceptive methods to prevent pregnancy. With the increasing success rate of these devices for contraceptive plans, married women are showing interest in adopting contraceptive methods to avoid unexpected pregnancies.

The increasing development of various contraceptive methods is another factor driving the market growth forward. In addition, increasing manufacturing of over-the-counter drugs by large pharmaceutical companies also helps with market growth. Increasing investment and research on the development of various types of products, drugs, and devices and increasing government support for the manufacturing of drugs is the other reason which helps the growth of the market. Furthermore, increasing clinical trials for decreasing the side effects of the pills and the devices used for the contraceptive and increasing clinical trials on new contraceptive methods such as using gels also demand the market during the forecast period. Additionally, increasing development of the application regarding the use of contraceptive pills by the developer also helps the market growth.

Increasing health risks after using the contraceptive method among many women is the primary factor restraining the market growth. In addition, the availability of alternative methods to prevent pregnancy and the lack of acceptance of these contraceptive methods among a few populations and areas also hampers the market growth in this region. Furthermore, the other factors that impede market growth are the lack of awareness about contraceptive methods, the long time for approval of the products and drugs, and the lack of skilled healthcare professionals in contraceptive surgeries.

Impact of COVID-19 on the APAC contraceptives market:

The COVID-19 epidemic has impacted negatively on healthcare services and technology around the world. It disrupted the demand and supply chain. Due to this pandemic, proper healthcare facilities and services were not available, as supply chains get disrupted, there were limited availability of contraceptives with product shortage and stockouts, lack of trained workers, and due to the lack of personal protective equipment to provide safe services, also due to the fear of COVID-19.

This research report on the APAC Contraceptives Market has been segmented & sub-segmented into the following categories:

By Drug Type: 

  • Contraceptive Pills
  • Topical Contraceptives
  • Contraceptive Injectable
  • Others (Contraceptive Gels, Jellies, and Creams)

By Medical Devices: 

  • Male Contraceptive Devices (Condoms)
  • Female Contraceptive Devices
    • Female Condoms
    • Intrauterine Devices
      • Hormonal IUD’s
      • Copper IUD’s
  • Contraceptive Sponges
  • Contraceptive Diaphragms
  • Subdermal Contraceptive Implants
  • Contraceptive Patches
  • Non-Surgical Permanent Contraceptive Devices

By End User: 

  • Hospitals
  • Home Care
  • Clinics
  • Ambulatory Surgical Centres

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Asia pacific holds the maximum share in the market growth due to increasing employed women and healthcare expenditures and increasing awareness programs by the healthcare organization and the government to use contraceptive methods for family women to prevent several pregnancies from controlling the heavy population in the region. They also inform people of the complication of having several pregnancies for a woman, which affects their health in the future. In addition, they are providing information regarding contraceptive methods through advertisements to aware people who are uneducated and living in rural areas.

China holds the maximum share in the market growth. China is one of the highest uses of contraceptives among the population. Nearly 84 percent of women use contraceptive methods after marriage and after the children's birth. Due to increasing government policies and traditions, rural have an increased impact on contraceptive methods in China. China's family planning policies target married women to take birth control options to manage the population in the country. Young people have no rule to use contraceptives in this county because they are unmarried. These people use contraceptive methods such as condoms and oral pills for abortion to prevent pregnancy. All these factors help develop market growth in the Asia Pacific region.

Increasing approval of the drugs is the main factor for the market's growth in Japan. Most of the Japan people are using condoms as a contraceptive way. The Pandemic provides an opportunity for the growth of contraceptive methods because a large number of populations during the pandemic period stay at home. Japan's government takes several measures to approve oral drugs to reduce the risk for women.

KEY MARKET PLAYERS:

A few of the notable companies dominating the APAC contraceptives market are Bayer HealthCare AG, Teva Pharmaceutical Industries Limited, Medisafe Distribution Inc, Pace Pharmaceuticals Inc., Medicines360, Church & Dwight, Co., Inc., Actavis, Inc., CooperSurgical, Inc., Merck & Co., Inc., Reckitt Benckiser plc, Mayer Laboratories, Inc., and Pfizer, Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]